Susquehanna International Group, LLP Arcutis Biotherapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$8.32 - $11.0 $303,680 - $401,500	-36,500 Reduced 42.59%	49,200 $457,000
Q2 2024 Aug 15, 2024	SELL	$7.24 - $12.53 $1.56 Million - $2.7 Million	-215,700 Reduced 71.57%	85,700 $797,000
Q1 2024 May 07, 2024	BUY	$3.25 - $11.77 $863,850 - $3.13 Million	265,800 Added 746.63%	301,400 $2.99 Million
Q4 2023 Feb 14, 2024	SELL	$1.84 - $4.82 $2,944 - $7,712	-1,600 Reduced 4.3%	35,600 $114,000
Q3 2023 Nov 14, 2023	BUY	$5.31 - $10.98 $6,902 - $14,274	1,300 Added 3.62%	37,200 $197,000
Q2 2023 Aug 11, 2023	BUY	$7.51 - $15.0 $269,609 - $538,500	35,900 New	35,900 $342,000
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $315,945 - $477,015	17,700 New	17,700 $338,000

197

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $557M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.